Testing an add-on drug for hard-to-control generalized convulsive seizures
Treatments studied
Part of Brain & nervous system clinical trials.
This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your guardian if you’re 12–17) can understand the study and sign consent/assent before starting
- You must be at least 12 years old, with BMI 40 or less
- Your seizures must fit primary generalized tonic-clonic seizures (with or without other generalized seizure types) for at least 1 year
- You’ve tried at least 2 seizure medicines at good doses and still don’t have seizure freedom
- Your seizure medicines must be stable (1 to 3 approved medicines) for at least 3 months before randomization
- You must reliably track seizures in a daily diary during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
Hear when a new Primary Generalized Tonic-Clonic Seizures trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.